US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Sarepta Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
News headline image
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
< Previous 1 2 3 4 Next >